Search alternatives:
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
larger decrease » marked decrease (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
larger decrease » marked decrease (Expand Search)
-
1701
-
1702
-
1703
Incidence number, ASIR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1704
-
1705
DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1706
-
1707
-
1708
-
1709
-
1710
-
1711
-
1712
-
1713
-
1714
-
1715
-
1716
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1717
-
1718
-
1719
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1720
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”